Nurix Therapeutics(NASDAQ) NRIX

Nurix Therapeutics helps the body destroy harmful proteins. It makes medicines for people with cancer and autoimmune diseases. The company uses artificial intelligence to find these new treatments.

What Nurix Is Developing

• NX-5948: Targeted protein degrader for patients with B-cell cancers and autoimmune diseases; currently in a Phase 2 clinical study.
• NX-2127: Oral medicine designed to break down specific signaling proteins, such as Bruton’s tyrosine kinase (BTK), in patients with aggressive B-cell lymphomas.
• NX-1607: Immuno-oncology drug candidate that blocks Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an enzyme that regulates how immune cells fight tumors.
• Drug Discovery Pipeline: Collaborative programs with large pharmaceutical companies to find new treatments using the proprietary DEL-AI platform.

Growth Through Global Partnerships

• Entered a global collaboration with Roche in June 2026 to develop and sell the lead drug candidate bexobrutideg (NX-5948).
• Extended a research partnership with Gilead in early 2024 to find new drug targets using the company discovery engine.
• Started a collaboration with Pfizer in September 2023 to create a new class of cancer medicines called degrader antibody conjugates.
• Expanded a multiyear agreement with Sanofi in March 2025 and May 2025 to license specific drug development candidates.

What Makes the Technology Different

The company uses a proprietary platform called DEL-AI that combines automated chemistry and artificial intelligence to design drugs faster. Its focus on E3 ligases allows it to target proteins that traditional medicines often cannot reach by triggering the body’s own protein disposal system.

Financial Facts and Figures

• Net loss was $176.7 million for the six-month period ended May 31, 2026.
• Total revenue was $15.3 million for the six-month period ended May 31, 2026, down from $62.5 million in the prior year.
• Cash, cash equivalents, and marketable securities totaled $443.5 million as of May 31, 2026.
• Collaboration and license agreements have provided $489.0 million in nondilutive financing as of May 31, 2026.
• Accumulated deficit reached $1.2 billion as of May 31, 2026.

Bottom Line

Nurix has shifted from an early-stage research firm to a clinical-stage company with multiple drug candidates in human trials. Its strategy relies on high-value partnerships with major pharmaceutical firms to fund the development of its protein-degrading technology.